Linked Life Data

21244218

Source:http://linkedlifedata.com/resource/pubmed/id/21244218

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2011-2-14
pubmed:abstractText
The development of biological drugs blocking tumour necrosis factor-alpha (TNF-?) has had a dramatic impact on the treatment of inflammatory arthritis in recent years. Golimumab is a fully human monoclonal antibody which inhibits TNF-?. It is licensed for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. In this review we evaluate the results of phase III studies using golimumab and explore the place of golimumab in the treatment of these diseases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1365-2060
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
43
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
133-41
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Golimumab - a new tool in the armoury against inflammatory arthritis.
pubmed:affiliation
Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, UK.
pubmed:publicationType
Journal Article, Review